>

>

Determine the better investment (in-house vs in-license) option for a small molecule drug

Service Areas
Therapeutic Areas

Central Nervous System

Client Type

Mid-size Biotech

Client Problems

  • A mid-side biotech company wanted to explore adding a small molecule inhibitor to a newly discovered target in their therapeutic area


  • They wanted to determine the cost : benefit ratio of two options


  • Develop the small molecule inhibitor in-house


  • In-license a small molecule inhibitor from another company

What We Did

  • We analyzed two investment options for the novel SM inhibitor


  • We build an model to accurately determine the potential NPV and sales for the two investment options


  • Included portfolio level and fundraising strategic considerations for each investment option


  • Determined the impact of Loss of Exclusivity and the IP value in each scenario and ran a sensitivity analysis on the model.

Our Results And Insight

  • Sales forecast & NPV for both scenarios


  • Flexible powerful valuation tool. Includes real time sensitivity analysis


  • Corporate Development Plan


  • New Insights

See other case studies

Commercial Strategy case studies >

Central Nervous System case studies >

Service Areas Details

Commercial Strategy (Valuation, Business Development)

Therapeutic Areas Details

Central Nervous System (Parkinson's, ALS)

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net